Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 415


Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.

Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK.

Mol Cancer Ther. 2013 May;12(5):747-58. doi: 10.1158/1535-7163.MCT-12-0811. Epub 2013 Mar 8.


Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.

Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK.

Int J Cancer. 2012 Oct 15;131(8):1930-40. doi: 10.1002/ijc.27439. Epub 2012 Mar 8.


Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.


Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.

Hui KF, Leung YY, Yeung PL, Middeldorp JM, Chiang AK.

Br J Haematol. 2014 Dec;167(5):639-50. doi: 10.1111/bjh.13089. Epub 2014 Aug 25.


Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.

Hui KF, Chiang AK.

Int J Cancer. 2014 Dec 15;135(12):2950-61. doi: 10.1002/ijc.28924. Epub 2014 May 5.


Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.

Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O.

Eur J Haematol. 2009 Jun;82(6):440-9. doi: 10.1111/j.1600-0609.2009.01239.x. Epub 2009 Feb 10.


PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM.

Clin Cancer Res. 2009 May 15;15(10):3354-65. doi: 10.1158/1078-0432.CCR-08-2365. Epub 2009 May 5. Erratum in: Clin Cancer Res. 2009 Jul 15;15(14):4784-5.


Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.

Sato A, Asano T, Ito K, Sumitomo M, Asano T.

BJU Int. 2012 Apr;109(8):1258-68. doi: 10.1111/j.1464-410X.2011.10533.x. Epub 2011 Sep 2.


The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.

Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL.

Leukemia. 2009 Aug;23(8):1507-14. doi: 10.1038/leu.2009.41. Epub 2009 Mar 12.


Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.

Hui KF, Cheung AK, Choi CK, Yeung PL, Middeldorp JM, Lung ML, Tsao SW, Chiang AK.

Int J Cancer. 2016 Jan 1;138(1):125-36. doi: 10.1002/ijc.29698. Epub 2015 Aug 11.


SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.

Emanuele S, Lauricella M, Carlisi D, Vassallo B, D'Anneo A, Di Fazio P, Vento R, Tesoriere G.

Apoptosis. 2007 Jul;12(7):1327-38.


Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.

Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J.

Eur J Haematol. 2008 May;80(5):407-18. doi: 10.1111/j.1600-0609.2008.01044.x. Epub 2008 Jan 23.


The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.

Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1131-40. doi: 10.1007/s00280-010-1455-1. Epub 2010 Sep 14.


Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.

Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI.

J Biol Chem. 2009 Jun 19;284(25):17102-9. doi: 10.1074/jbc.M809090200. Epub 2009 Apr 22.

Items per page

Supplemental Content

Support Center